Checkpoint Therapeutics is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.44 – a decrease of 0.2% over the previous week. Checkpoint Therapeutics employs 23 staff and has a trailing 12-month revenue of around $78,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.44 |
|---|---|
| 52-week range | $1.36 - $3.62 |
| 50-day moving average | $2.27 |
| 200-day moving average | $2.04 |
| Wall St. target price | $17.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.71 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.435 from 2024-10-11
| 1 week (2024-10-07) | -0.20% |
|---|---|
| 1 month (2024-09-13) | 5.87% |
| 3 months (2024-07-12) | 3.62% |
| 6 months (2024-04-12) | 36.80% |
| 1 year (2023-10-13) | 30.21% |
|---|---|
| 2 years (2022-10-14) | 144.48% |
| 3 years (2021-10-14) | 3.39 |
| 5 years (2019-10-14) | 19.95% |
| Revenue TTM | $78,000 |
|---|---|
| Gross profit TTM | $-48,185,000 |
| Return on assets TTM | -316.7% |
| Return on equity TTM | -1220.38% |
| Profit margin | 0% |
| Book value | $-0.37 |
| Market Capitalization | $106.7 million |
TTM: trailing 12 months
We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.
Checkpoint Therapeutics's shares were split on a 1:10 basis on 5 December 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Checkpoint Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Checkpoint Therapeutics shares which in turn could have impacted Checkpoint Therapeutics's share price.
Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $1.36 up to $3.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.302. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Checkpoint Therapeutics, Inc. , a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc. , to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.